<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1841</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1841 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  JOE DANIELSEN</p>

<p class=bpuSponsor>District 17 (Middlesex and Somerset)</p>

<p class=bpuSponsor>Assemblywoman  VERLINA REYNOLDS-JACKSON</p>

<p class=bpuSponsor>District 15 (Hunterdon and Mercer)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>Co-Sponsored by:</p>

<p class=bpuSponsor>Assemblymen Simonsen, McClellan, Assemblywoman Matsikoudis,
Assemblyman Schaer, Assemblywoman Speight, Assemblyman Rodriguez, Assemblywoman
Ramirez, Assemblyman Schnall, Assemblywoman Swift, Assemblyman DeAngelo,
Assemblywomen Donlon, Peterpaul, Assemblymen Spearman, Azzariti Jr., Abdelaziz,
Assemblywoman Katz, Assemblyman Scharfenberger, Assemblywomen Sumter, Carter,
Assemblymen Rumpf, Venezia, Kennedy, Stanley and Karabinchak</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Expands requirements for health insurance carriers
concerning prostate cancer screening and requires coverage be provided without
cost sharing. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning health insurance coverage for prostate
cancer screening and amending P.L.1996, c.125 and supplementing various parts
of the statutory law.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    Section 1 of P.L.1996,
c.125 (C.17:48E-35.13) is amended to read as follows:.</p>

<p class=MsoNormal style='line-height:150%'>     1.    <u>a.</u>  No health
service corporation contract providing hospital or medical expense benefits <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>for groups
with greater than 49 persons<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
shall be delivered, issued, executed or renewed in this State, or approved for
issuance or renewal in this State by the Commissioner of Insurance on or after
the effective date of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>this
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.1996,
c.125 (C.17:48E-35.13 et al.)</u>, unless the contract provides benefits to any
named subscriber or other person covered thereunder for expenses incurred in
conducting an annual <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>medically
recognized diagnostic examination including, but not limited to, a digital
rectal examination and a prostate-specific antigen test for men age 50 and over
who are asymptomatic and for men age 40 and over with a family history of
prostate cancer or other prostate cancer risk factors<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>prostate cancer screening</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract <u>except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the benefits shall be imposed</u>.</p>

<p class=MsoNormal style='line-height:150%'>     This section shall apply to
all health service corporation contracts in which the health service
corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     <u>b.    As used in this
section:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(1)  urinary analysis;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(2)  serum biomarkers;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.1996, c.125, s.1)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    Section 2 of P.L.1996,
c.125 (C.17:48-6p) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     2. a. No hospital service
corporation contract providing hospital or medical expense benefits <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>for groups
with greater than 49 persons<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
shall be delivered, issued, executed or renewed in this State, or approved for
issuance or renewal in this State by the Commissioner of Insurance on or after
the effective date of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>this
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.1996,&nbsp;c.125
(C.17:48E-35.13 et al.)</u>, unless the contract provides benefits to any named
subscriber or other person covered thereunder for expenses incurred in
conducting an annual <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>medically
recognized diagnostic examination including, but not limited to, a digital
rectal examination and a prostate-specific antigen test for men age 50 and over
who are asymptomatic and for men age 40 and over with a family history of
prostate cancer or other prostate cancer risk factors<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>prostate cancer screening</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract <u>except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the benefits shall be imposed</u>.</p>

<p class=MsoNormal style='line-height:150%'>     This section shall apply to
all hospital service corporation contracts in which the hospital service
corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <u>As used in this
section:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(1)  urinary analysis;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(2)  serum biomarkers;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.1996, c.125, s.2)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    Section 3 of P.L.1996,
c.125 (C.17:48A-7n) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     3. a. No medical service
corporation contract providing hospital or medical expense benefits <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>for groups
with greater than 49 persons<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
shall be delivered, issued, executed or renewed in this State, or approved for
issuance or renewal in this State by the Commissioner of Insurance on or after
the effective date of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>this
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.1996,
c.125 (C.17:48E-35.13 et al.)</u>, unless the contract provides benefits to any
named subscriber or other person covered thereunder for expenses incurred in
conducting an annual <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>medically
recognized diagnostic examination including, but not limited to, a digital
rectal examination and a prostate-specific anitgen test for men age 50 and over
who are asymptomatic and for men age 40 and over with a family history of
prostate cancer or other prostate cancer risk factors<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>prostate cancer screening</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract <u>except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the benefits shall be imposed</u>.</p>

<p class=MsoNormal style='line-height:150%'>     This section shall apply to
all medical service corporation contracts in which the medical service
corporation has reserved the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <u>As used in this
section:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(1)  urinary analysis;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(2)  serum biomarkers;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.1996, c.125, s.3)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    Section 4 of P.L.1996,
c.125 (C.17B:27-46.1o) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     4. a. No group health
insurance policy providing hospital or medical expense benefits <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>for groups
with greater than 49 persons<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
shall be delivered, issued, executed or renewed in this State, or approved for
issuance or renewal in this State by the Commissioner of Insurance on or after
the effective date of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>this
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.1996,&nbsp;c.125&nbsp;(C.17:48E-35.13
et al.)</u>, unless the policy provides benefits to any named insured or other
person covered thereunder for expenses incurred in conducting an annual <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>medically
recognized diagnostic examination including, but not limited to, a digital
rectal examination and a prostate-specific antigen test for men age 50 and over
who are asymptomatic and for men age 40 and over with a family history of 
prostate cancer or other prostate cancer risk factors<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>prostate cancer screening</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the policy <u>except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the benefits shall be imposed</u>.</p>

<p class=MsoNormal style='line-height:150%'>     This section shall apply to
all group health insurance policies in which the health insurer has reserved
the right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <u>As used in this
section:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(1)  urinary analysis;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(2)  serum biomarkers;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.1996, c.125, s.4)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    Section 5 of P.L.1996,
c.125 (C.26:2J-4.13) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     5. a. A certificate of
authority to establish and operate a health maintenance organization in this
State shall not be issued or continued by the Commissioner of Health on or
after the effective date of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>this
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.1996,
c.125 (C.17:48E-35.13 et al.)</u> unless the health maintenance organization
provides health care services to any enrollee which include an annual <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>medically
recognized diagnostic examination including, but not limited to, a digital
rectal examination and a prostate-specific antigen test for men age 50 and over
who are asymptomatic and for men age 40 and over with a family history of 
prostate cancer or other prostate cancer risk factors<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b> <u>prostate cancer screening</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The health care services shall
be provided to the same extent as for any other medical condition under the
contract <u>except that no deductible, coinsurance, copayment, or any other
cost-sharing requirement on the services shall be imposed</u>.</p>

<p class=MsoNormal style='line-height:150%'>     The provisions of this section
shall apply to all contracts for health care services by health maintenance
organizations under which the right to change the schedule of charges for
enrollee coverage is reserved.</p>

<p class=MsoNormal style='line-height:150%'>     b.    <u>As used in this section:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as directed by a health care provider,
including, but not limited to:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(1)  urinary analysis;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(2)  serum biomarkers;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf:  P.L.1996, c.125, s.5)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    (New section) a.  (1)  Every
individual health insurance policy that provides hospital or medical expense
benefits and is delivered, issued, executed or renewed in this State pursuant
to chapter 26 of Title 17B of the New Jersey Statutes, or approved for issuance
or renewal in this State by the Commissioner of Banking and Insurance, on or
after the effective date of this act shall provide coverage for an annual
prostate cancer screening. </p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the services shall be imposed.</p>

<p class=MsoNormal style='line-height:150%'>     The provisions of this section
shall apply to all policies in which the insurer has reserved the right to
change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging, including,
but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    (New section) a.  (1)  Every
individual health benefits plan that provides hospital or medical expense
benefits and is delivered, issued, executed or renewed in this State pursuant
to P.L.1992, c.161 (C.17B:27A-2 et seq.) or approved for issuance or renewal in
this State on or after the effective date of this act shall provide benefits
for an annual prostate cancer screening.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the services shall be imposed.</p>

<p class=MsoNormal style='line-height:150%'>     The provisions of this section
shall apply to all health benefits plans in which the carrier has reserved the
right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.    (New section) a. Every
small employer health benefits plan that provides hospital or medical expense
benefits and is delivered, issued, executed or renewed in this State pursuant
to P.L.1992, c.162 (C.17B:27A-17 et seq.) or approved for issuance or renewal
in this State on or after the effective date of this act shall provide benefits
for an annual prostate cancer screening. </p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the services shall be imposed.</p>

<p class=MsoNormal style='line-height:150%'>     The provisions of this section
shall apply to all health benefits plans in which the carrier has reserved the
right to change the premium.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a physician, including, but
not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     9.    (New section) a.  The
State Health Benefits Commission shall ensure that every contract purchased by
the commission on or after the effective date of this act that provides
hospital or medical expense benefits shall provide coverage for an annual
prostate cancer screening.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract except
that no deductible, coinsurance, copayment, or any other cost-sharing
requirement on the services shall be imposed.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen
test and associated laboratory work.  Prostate cancer screening shall also
include subsequent follow up testing as direct by a health care provider,
including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     10.  (New section) a.  The
School Employees Health Benefits Commission shall ensure that every contract
purchased by the commission on or after the effective date of this act that
provides hospital or medical expense benefits shall provide coverage for an
annual prostate cancer screening.</p>

<p class=MsoNormal style='line-height:150%'>     The benefits shall be provided
to the same extent as for any other medical condition under the contract except
that no deductible, coinsurance, copayment, or any other cost-sharing requirement
on the services shall be imposed.</p>

<p class=MsoNormal style='line-height:150%'>     b.    As used in this section:</p>

<p class=MsoNormal style='line-height:150%'>     Prostate cancer screening
means medically viable methods for the detection and diagnosis of prostate
cancer, which includes a digital rectal exam and the prostate-specific antigen test
and associated laboratory work.  Prostate cancer screening shall also include
subsequent follow up testing as direct by a health care provider, including,
but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging, including,
but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     11.  This act shall take
effect on the 90th day next following the date of enactment and shall apply to
all contracts and policies delivered, issued, executed, or renewed on or after
that date. </p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill requires health,
hospital, and medical service corporations, health maintenance organizations,
and commercial group health insurers to provide coverage for an annual prostate
cancer screening without cost sharing.  Under current law, these health
insurance carriers are required only to provide coverage for an annual
medically recognized diagnostic examination including, but not limited to, a
digital rectal examination and a prostate-specific antigen test for men age 50
and over who are asymptomatic and for men age 40 and over with a family history
of  prostate cancer or other prostate cancer risk factors.  The bill expands
the definition of prostate cancer screening to mean medically viable methods
for the detection and diagnosis of prostate cancer, which includes a digital
rectal exam and the prostate-specific antigen test and associated laboratory
work.  Prostate cancer screening shall also include subsequent follow up
testing as direct by a physician, including, but not limited to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)  urinary analysis;</p>

<p class=MsoNormal style='line-height:150%'>     (2)  serum biomarkers;</p>

<p class=MsoNormal style='line-height:150%'>     (3)  medical imaging,
including, but not limited to, magnetic resonance imaging.</p>

<p class=MsoNormal style='line-height:150%'>     The bill also extends the
prostate cancer screening requirements to commercial individual health
insurers, health benefits plans <br clear=all style='page-break-before:always'>
issued pursuant to the New Jersey Individual Health Coverage and Small Employer
Health Benefits Programs, the State Health Benefits Program, and the School
Employees Health Benefits Program, which are not required to provide this
coverage under current law. </p>

</div>

</body>

</html>
